Forest Laboratories — Merger or Acquisition (February 2014)
23 slides from Forest Laboratories's merger presentation, Feb 18, 2014
Slide 1: Creating a New Model in Specialty Pharmaceutical Leadership
Creating a New Model in Specialty Pharmaceutical Leadership Filed by Forest Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Forest Laboratories, Inc Commission File No.: 1-5438
Slide 2: Important Information For Investors and Shareholders
Important Information For Investors and Shareholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitatio
Slide 3: Actavis Cautionary Statement Regarding Forward-Looking Statements
Actavis Cautionary Statement Regarding Forward-Looking Statements Statements contained in this communication that refer to Actavis’ estimated or anticipated future results, including estimated synergies, or other non-historical facts are forward-looking statements that reflect Actavis’ current persp
Slide 4: Forest Cautionary Statement Regarding Forward-Looking Statements
Forest Cautionary Statement Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the benefits of the acquisit
Slide 5: Presentation Overview
Presentation Overview • Transaction Overview • An Innovative New Model in Specialty Pharmaceutical Leadership • Forest Overview • Summary
Slide 6: Proposed Transaction Terms
Proposed Transaction Terms • Equity and Cash transaction valued at approximately $25 B - 25% Premium to Forest closing price as of 2/14/2014 - 70/30 equity and cash split - $26.04 in cash + 0.3306 share of ACT/share of FRX • Pro Forma Forest ownership of ~35% shares of Actavis • Cash portion funded
Slide 7: Creating an Innovative New Model in Specialty Pharmaceutical Leadership
Creating an Innovative New Model in Specialty Pharmaceutical Leadership Enhanced size and scale Broad & diverse portfolio with multiple blockbuster therapeutic franchises Balanced portfolio of branded and generic pharmaceuticals Exceptionally strong global commercial capabilities create high value t
Slide 8: Balanced Revenue Portfolio
Balanced Revenue Portfolio of North American Brand, North American Generic, International and Distribution Based on 2014 proforma combined revenue
Slide 9: Financially Compelling Combination
Financially Compelling Combination • Approximately $15 billion annual revenue generatio n — Approximately 50/50 brand/generic • Expected double-digit accretion to non-GAAP earnings, including synergies, in 2015 and 2016 • Greater than $4 billion annual free cash flow in 2015 — Expect to maintain inv
Slide 10: Broad & Diverse Portfolio with Multiple Blockbuster Therapeutic Franchises
Broad & Diverse Portfolio with Multiple Blockbuster Therapeutic Franchises
Slide 11: Emerging and Sustainable Portfolios in New Categories
CARDIOVASCULAR DERM INFECTIOUS DISEASE RESPIRATORY CYSTIC FIBROSIS Emerging and Sustainable Portfolios in New Categories Added from combination
Slide 12: Exceptionally Strong Commercial Capabilities Create High Value to Customers
Exceptionally Strong Commercial Capabilities Create High Value to Customers • Enhanced profile: size, scale and product diversification bring high value to customers – physicians, hospitals, health plans and distribution channels • World-class global commercial organization competing across multiple
Slide 13: Continued Strong Investment in R&D with Over $1 Billion Expected in Year One
Continued Strong Investment in R&D with over $1 Billion Expected in Year One • Continued investment in strong pipeline assets across all therapeutic categories • Continued strong investment in generic R&D to maintain strong global pipeline - Continue to invest in differentiated products including re
Slide 14: Combined Specialty Brands Pipeline
Colvir Albaconazole VVC Esmya®-Fibroids (US) Diafert™ WC3011 E2 Vaginal Cream Metronidazole 1.3% Vaginal Gel E4/Progestin OC Levosert™ Contraception Progestin Only Patch Amg/Act Herceptin® WC3043 Udenafil ED WC3055 Udenafil BPH Rapaflo® NextGen WC3035 Sarecycline WC2055 Doxycycline NextGen Oxybutyni
Slide 15: Forest Overview
Overview
Slide 16: Forest – Overview and Strategy
BUSINESS development DRUG Marketed Drugs NDA EXECUTION AN EXCEPTIONAL COMPANY ENGINE commercial Specialty pharmaceutical company focused on large primary care and subspecialty markets Key strategy building blockbuster therapeutic line calls to create economies and relevance Forest – Overview and Str
Slide 17: Recent Strategic Initiatives Have Rejuvenated Forest
Recent Strategic Initiatives Have Rejuvenated Forest Commenced Project Rejuvenate to achieve $500 M in cost reductions Acquired Saphris for $240 M Leveraged balance sheet with $1.2 B in first ever bond offering in December and $1.8 B offering in January for Aptalis acquisition Achieved NAMENDA XR ®
Slide 18: Forest Has Strong Drug Development Capabilities and Commercial Execution
Forest Has Strong Drug Development Capabilities and is Focused on Commercial Execution • Next 9 strategy executed well • 7 regulatory approvals since 2009 • History of first cycle approvals • New products contributed 44% of sales and grew 59% year- over-year in most recent quarter
Slide 19: Recent Acquisition of Aptalis
Recent Acquisition of Aptalis • Aptalis is an excellent strategic fit Diversifies Forest offerings in key therapeutic areas GI franchise in the US complements Linzess business CF franchise in Europe complements Colobreathe business Significantly improves Forest profitability in Canada • Aptalis prod
Slide 20: Summary of a Transformational Combination
Summary of a Transformational Combination
Slide 21: ~$1 Billion in Annual Synergies
~$1 Billion in Annual Synergies • ~$1 Billion Pre-Tax Operational and Tax Synergies • Majority of the synergies are expected to take place in first 12 months following close – Total synergies realized in first 3 years after acquisition close • Excludes any manufacturing and revenue synergies • Tax s
Slide 22: Next Steps
Next Steps • Successful Completion of Transaction Requires: – Approval by shareholders of both companies – Regulatory review and approval including Hart-Scott- Rodino review • Anticipated close mid-year 2014 • Management teams from both companies to immediately begin pre-integration activities to ma
Slide 23: Forest Laboratories, Inc.
a ; MK & Forest Laboratories, Inc.
Forest Laboratories — Merger or Acquisition (February 2014) on 6ix